Medical release archive

Farxiga study showed reduced progression of kidney disease or renal death in patients with type-2 diabetes

Fasenra reduces oral corticosteroid use and maintains long-term efficacy and safety profile in severe eosinophilic asthma

AstraZeneca enters strategic collaboration with Transgene to develop innovative oncolytic virus immunotherapies

AstraZeneca announces two Lancet Oncology publications of Phase I dose-expansion results of trastuzumab deruxtecan in HER2-positive metastatic breast and gastric cancer

Farxiga heart failure research broadened with new Phase III DETERMINE trials

AstraZeneca supports new global recommendations on asthma care

Phase III TREAT trial provides evidence on the use of Brilinta in high-risk patients treated with pharmacological thrombolysis

Imfinzi demonstrates clinical activity in Stage IV, 1st-line non-small cell lung cancer in Phase III MYSTIC trial

New PEGASUS-TIMI 54 sub-analyses provide direction on selecting patients most likely to benefit from long-term treatment with Brilinta (ticagrelor)

First patients enrolled in Phase IIIb PONENTE trial evaluating the elimination of oral corticosteroids with Fasenra in severe eosinophilic asthma